Holen Sie sich die Stockscreener-App
35.42
0.60%
0.21
Handel nachbörslich:
35.42
Schlusskurs vom Vortag:
$35.21
Offen:
$35.11
24-Stunden-Volumen:
1.33M
Relative Volume:
0.61
Marktkapitalisierung:
$5.75B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-328.94M
KGV:
-14.46
EPS:
-2.4487
Netto-Cashflow:
$-266.00M
1W Leistung:
+0.08%
1M Leistung:
-4.48%
6M Leistung:
+122.77%
1J Leistung:
+642.56%
1-Tages-Spanne:
$34.80
$35.87
1-Wochen-Bereich:
$33.82
$39.41
52-Wochen-Spanne:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Firmenname
Cogent Biosciences Inc
Sektor
Branche
Telefon
617-945-5576
Adresse
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
35.42 | 5.71B | 0 | -328.94M | -266.00M | -2.4487 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2025-11-10 | Hochstufung | Stifel | Hold → Buy |
| 2025-11-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-10-16 | Eingeleitet | Stifel | Hold |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-11 | Herabstufung | Needham | Buy → Hold |
| 2024-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Eingeleitet | Citigroup | Buy |
| 2023-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-12-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-04-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-09 | Fortgesetzt | Jefferies | Buy |
| 2020-12-23 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA - Sahm
COGT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Cogent Biosciences Inc To Discuss Full SUMMIT Data at ASH Transcript - gurufocus.com
[Form 4] Cogent Biosciences, Inc. Insider Trading Activity - Stock Titan
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - The Globe and Mail
Technical Reactions to COGT Trends in Macro Strategies - news.stocktradersdaily.com
Cogent Biosciences, Inc.Common Stock (NQ: COGT - The Chronicle-Journal
Cogent Biosciences, Inc. (COGT) stock price, news, quote and history - Yahoo Finance UK
Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' (NASDAQ:COGT) - Seeking Alpha
Dip Buying: What are analysts price targets for Cogent Biosciences Inc2026 Top Decliners & Risk Controlled Daily Trade Plans - baoquankhu1.vn
COGT Forecast, Price Target & Analyst Ratings | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Cogent Biosciences (COGT) Is Up 5.5% After FDA NDA Filing For Bezuclastinib In GISTHas The Bull Case Changed? - Sahm
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors - Investing News Network
Cogent Biosciences (NASDAQ:COGT) Stock Price Down 10.2%Should You Sell? - MarketBeat
Biotech Stocks To ConsiderApril 1st - MarketBeat
Cogent Biosciences (COGT) Advances Bezuclastinib Application - GuruFocus
Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors in US - marketscreener.com
Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors - marketscreener.com
Cogent files new GIST drug after trial cut progression risk 50% - Stock Titan
Fairmount funds sells Cogent Biosciences (COGT) shares for $242.6m By Investing.com - Investing.com Canada
Form 144 | Cogent Biosciences(COGT.US) Director Proposes to Sell 242.62 Million in Common Stocks - Moomoo
COGT (NASDAQ) Form 144 shows proposed 7.0M share sale after conversion - Stock Titan
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts - Proactive financial news
Hennion & Walsh Asset Management Inc. Buys 37,938 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding - AOL.com
Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation - MSN
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
Assenagon Asset Management S.A. Trims Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers - TipRanks
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - AOL.com
Vanguard disaggregates holdings; Cogent Biosciences (COGT) shows 0% ownership - Stock Titan
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - AOL.com
Aug Analyst Calls: Is Cogent Biosciences Inc forming a double bottomPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Assessing Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Rising Institutional Interest - Sahm
A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions - Yahoo Finance
Trading the Move, Not the Narrative: (COGT) Edition - Stock Traders Daily
RTW Investments Increases Cogent Biosciences Stake to 2.7% of PortfolioNews and Statistics - IndexBox
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million - Intellectia AI
Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio UpdateNews and Statistics - IndexBox
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - The Motley Fool
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Biotech share surges 372% before being sold as latest selection climbs 40% in 2026 - Bitget
FDA accepts Cogent’s drug filing for treatment of rare blood disorder - MSN
Cogent Biosciences stock climbs after FDA accepts key drug application - MSN
HC Wainwright Analysts Lift Earnings Estimates for COGT - MarketBeat
Is Cogent Biosciences (COGT) one of the best multibagger stocks to buy according to billionaires? - MSN
Finanzdaten der Cogent Biosciences Inc-Aktie (COGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cogent Biosciences Inc-Aktie (COGT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Sale |
34.66 |
7,000,000 |
242,620,000 |
5,503,418 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
36.40 |
3,500,000 |
127,400,000 |
5,503,418 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):